相关实验视频

Updated: Jan 8, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

针对乳腺癌:新二胺作为强大的EG5抑制剂

Dhirajkumar Nikam^1,2, Anurekha Jain¹, Shraddha Vetale²

¹Department of Pharmaceutical Chemistry, Oriental University, Indore, Madhyapradesh, 453555, India.

Medicinal chemistry (Shariqah (United Arab Emirates))

|December 15, 2025

概括

新的二皮里米丁-皮拉-福化合物被合成并测试了乳腺癌活性. 化合物3j对MCF-7细胞显著抑制了生长,显示出作为一种强大的抗癌剂的前景.

科学领域:

药用化学医学化学
药物发现药物发现药物发现
有机合成有机合成

背景情况:

乳腺癌需要新型治疗方法,以提高安全性.
狄氏胺基 (DHPM),皮拉和福的支架显示出不同的药理潜力.
脚手架跳跃是一种设计新药候选药物的策略.

研究的目的:

使用脚手架跳跃设计和合成一种新的DHPM-Pyrazole-Benzofuran核心.
评估合成化合物对抗乳腺癌的抗癌潜力.
为了研究与基因素螺旋蛋白的结合相互作用Eg5.

主要方法:

通过Biginelli协议合成化合物 (3a-3j).
使用FTIR,1H NMR和质谱学进行表征.
对Eg5 (1Q0B) 的分子对接和对MCF-7细胞的SRB测定.

主要成果:

化合物3j对MCF-7细胞表现出显著的抑制生长活性 (GI50=24.08μM),表现优于Monastrol (GI50=32μM).
化合物3j与Eg5蛋白残留物GLU-116和ARG-119产生强烈的相互作用.
对接研究表明,化合物3j在Eg5.5的全osteric位点上具有有利的结合.

结论:

化合物3j是一种强大的细胞毒剂,具有显著的乳腺癌增长抑制活性.
新的DHPM-Pyrazole-Benzofuran支架对开发新的抗癌药物充满希望.
准Eg5蛋白是乳腺癌治疗的可行策略.

关键词:

乳腺癌乳腺癌乳腺癌在 DHPM 的情况下,它是 DHPM.这是一种EG5抑制剂.在MCF-7中使用.莫纳斯托尔公司.在脚手架上跳跃跳跃.

更多相关视频

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...